Chinese researchers describe a new ultrasensitive method for detecting exosomal microRNAs that have emerged as ideal biomarkers for early clinical diagnostics. Among other advanced techniques, the electrochemiluminescent biosensor employs a 3D walking nanomotor-mediated CRISPR-Cas12a and tetrahedral DNA nanostructure-modified nanoemitters.
Monday, we reported on a novel CRISPR-Cas13d therapy for Huntington’s disease developed by Johns Hopkins and University of California San Diego researchers. Huntington's disease is fatal, and despite decades of research, there is no known cure. The new approach, however, uses Cas13d to deplete cells for the mutant mRNA transcripts that contribute to the pathogenesis of the disease.
To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.